eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

vol. 10
Original paper

Effectiveness and safety of a robot-assisted 3D personalized template in 125I seed brachytherapy of thoracoabdominal tumors

Xiaodong Ma, Zhiyong Yang, Shan Jiang, Bin Huo, Qiang Cao, Shude Chai, Haitao Wang

J Contemp Brachytherapy 2018; 10, 4: 368–379
Online publish date: 2018/08/31
Article file
- effectiveness.pdf  [2.52 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Malignant tumors are the second leading cause of deaths in the United States, and expected to surpass heart disease as the first factor leading to death [1]. In China, it is becoming one of the leading cause of deaths and an important public health issue. Among the malignant tumors, the incidence and mortality of lung cancer are the highest, followed by liver cancer, gastric cancer, and esophageal cancer [2], and they are all located in thorax and abdomen. Currently, chemotherapy, surgical resection, and radiotherapy are the standard treatment methods for malignant tumors. It is known that different treatment methods have different indications. The same tumor may have different sensibilities to different treatment methods, leading to a different therapeutic effect. Chemotherapy, such as targeted therapy, is an emerging cancer treatment and has great effectiveness for patients with advanced metastases. But the treatment effect will vary due to the unique physique of each person, and chemotherapeutic agents usually have serious side effects on the patient [3,4,5]. Similarly, surgical resection will bring greater trauma to the patients’ body and thus cause complications to the patient [6,7]. For a long time, radiotherapy was also one of the treatment methods for cancers because it is suitable for a variety of indications. External beam radiation was the main method of radiotherapy but it causes damage to the normal tissue around the tumor [8]. With the development of medical equipment and technology, three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and image-guided radiation therapy (IGRT) make great achievements in cancer treatment and greatly improve the precision of radiotherapy.
125I seeds implantation as a form of precise radiotherapy for cancer treatment has a history of over 100 years and has been applied to various solid tumors [9,10,11,12,13]. Compared with the conventional treatment, it has three advantages. Firstly, the irradiation affects only a very localized area around the radiation sources. Exposure to radiation of healthy tissues farther away from the sources is therefore reduced. In addition, if the patient moves or if there is any movement of the tumor within the body during treatment, the radiation sources retain their correct position in relation to the tumor. These characteristics of brachytherapy provides advantages over external beam radiotherapy: the tumor can be treated with very high doses of localized radiation while reducing the probability of unnecessary damage to surrounding healthy tissues.
Secondly, a permanent implantation. Once the seeds are implanted into the tumor, it can provide continuous irradiation dose. Therefore, the patient does not require multiple hospitalizations for treatment. It has been proved that 125I seed brachytherapy was feasible with minimal radiation-related morbidity [14,15,16].
In the 125I seed brachytherapy, the conventional coplanar template (CCT) is usually selected as a guiding tool [17]. With this template, the needles can be punctured along the planned paths. But all the needles are in a fixed direction, perpendicular to CCT. To overcome this drawback, the 3D personalized template (3DPT) was developed. It is a non-coplanar template, reconstructed from the patient computed tomography (CT) images and dose planning results. The direction of each needle can be designed more individually compared with CCT. In recent years, CCT-guided seed implantation was gradually replaced by 3DPT. Zhang et al. [18] successfully performed 125I seed implantation surgeries on thirty-one patients, with recurrent and locally advanced malignant tumors of the head and neck under the guidance of 3DPT. The research demonstrated that this approach can facilitate easier and more accurate implantation with 3DPT in clinical practice. Wang et al. [19] used 3DPT to perform surgeries on sixteen patients, with paravertebral and retroperitoneal malignant tumors. Similarly, Wang’s group and Han’s group performed 125I seed implantation successfully under CT guidance assisted by 3DPT for the treatment of rectal cancer, liver cancer, and cervical lymph node recurrence [20,21,22]. All those clinical reports have achieved great success. Therefore, 125I seed implantation based on 3DPT for cancer treatment is possible. However, the research about the 3DPT focuses mainly on performing clinical surgeries. To our best of knowledge, there were no related evaluations of its effectiveness and safety reported. In this research, the effectiveness and safety of 125I seed implantation based on a robot-assisted 3DPT were evaluated compared with that based on CCT. For this purpose, a variety of comparable surgical cases after receiving 125I seed brachytherapy were selected and analyzed.

Material and methods


From 2013 to 2015, 93 patients with thoracoabdominal tumors were treated, and 52 of them were eligible for robot-assisted 3D personalized template-guided 125I seed brachytherapy (RTDPTB). Among these 52 patients, 43 patients (82.7%) had complete information on the treatment and follow-up. Therefore, the 43 patients were involved in this analysis. For all the patients, their cancers were confirmed through CT-guided biopsy. All 43 participants treated with RTDPTB were considered as the experimental group. Meanwhile, five years before the 3DPT was applied to 125I seed brachytherapy, there were 108 patients who received conventional coplanar template-guided 125I seed brachytherapy (CCTB), among which 86 (79.6%) patients had complete information on the treatment and follow-up. Out of 86 patients, 51 with similar tumors were selected for comparison, and the 51 patients were considered as the control group. The patients’ demographic and clinical characteristics are summarized in Table 1. There were 27 men and 16 women, with median age of 56 years (range, 38-75) in RTDPTB. In CCTB, there were 36 men and 15 women, with median age of 58 years (range, 40-69). The Eastern Cooperative Oncology Group (ECOG) evaluation was 0-1 points in all patients.

Therapeutic method

The robot and 3DPT were developed in our laboratory. In this research, the robot achieved the accurate positioning of 3DPT and the detailed description of the robot is in reference [23]. 3DPT was created in TPS through preoperative planning and saved as “stl” format. Then, the “stl” model was imported into the 3D printing machine (Israel, Stratasys Objet30 pro). The material used for printing 3DPT is a photosensitive resin, with acrylic monomer as the main component. The printing time of a 3DPT is about 15-20 hours, depending on the size of the template. Because whether using CCT or 3DPT in a surgery, there are about two days for preoperative planning and other preparations, and 3DPT can be printed completely during this time. During these two days, no procedure was implemented, whether using CCTB or RTDPTB, so there was no impact on the treatment delivery. The advantage of 3DPT was the ability to match well with the patient’s skin, as shown in Figure 1. Using 3DPT, the entry and path of needles were easily determined to avoid damage of vital structures such as large vessels. Before surgery, the low-temperature disinfection method was used to deal with 3DPT. Then, 3DPT was fixed on the end effector of the robot.

Seed implantation

125I seeds used in the surgery were provided by China Institute of Atomic Energy (Beijing, China). The internal dimension of the sliver rod is 3.0 mm x 0.5 mm and the thickness of the titanium capsule is 0.05 mm. The median radioactivity of the seed was 2.59 × 107 Bq or 0.7 mCi (range, 2.22–2.96 × 107 Bq or 0.6-0.8 mCi) and the energy was 27-35 keV, half-life 59.4 days. Before the surgery, the radioactivity was determined using an activity meter (CRC-15).

Preimplantation preparation

Before the seed implantation surgery, patients received a CT scanning based on a thickness of 2.5 mm. During the CT scanning, the patient was wrapped in a negative pressure vacuum pad in order to maintain the patient’s posture before surgery and remain unchanged during surgery. It should be noted that some markers were attached on the patient skin. The markers are metal balls, less than 1 mm in diameter, and the location of the marker is aligned with the laser line in the CT room. The negative pressure vacuum pad is used to maintain the patient’s posture. The markers and the laser line are used to record the position of the patient on CT table. The repositioning process was completed by the markers, laser line, and the negative pressure vacuum pad. CT data was saved and exported in DICOM format.

Implantation plan

The seed implantation plan was achieved using the Body Tumor Brachytherapy Treatment Planning System (BT-BTPS, Tianjin University, Tianjin, China), which was the latest research achievement in our laboratory.
The dose calculation in BT-BTPS uses the formalism of “TG43” accord­ing to recommendations by the American Association of Physicists in Medicine [24,25]. In this surgery, BT-BTPS will achieve the following steps [13]: 1. Read information from CT images (Figure 2A); 2. Outline gross tumor volume (GTV), clinical target volume (CTV), and planning target volume (PTV); 3. Reconstruct the tumor target and vital organs (Figure 2B); 4. Design the needle direction for seed implantation and avoid vital organs at the same time (Figure 2C); 5. Show a real-time display of the isodose line and isodose surface (Figures 2D and 2E); 6.
Extract the patient’s skin data to create 3DPT (Figure 2F). In step 4, when designing a needle paths, the bones and vital organs should be avoided, and interference between needles in different slices should also be eluded. Under the above conditions, it is recommendable to choose the needle path where the tumor is closer to the skin. In step 6, 3DPT was created through clipping the patient’s skin. Since the positions of the tumor target and the needle were determined before, 3DPT can be guaranteed to cover the tumor target completely by clipping the skin. That is to say, 3DPT showed an advantage that it was customized according to the specific requirement of every patient, while the shape and size of CCT are unalterable. Moreover, TPS can calculate the number of seeds and needles as well as the depth of every needle. To meet the requirements of dose calculation and the dose optimization, prescription dose D90 was set to 110-140 Gy. In this research, the dose optimization is achieved manually using the dose–volume histogram (DVH). The DVH should meet the following conditions: V100 > 90%, V150 < 50%, V200 < 20%. In this process, the radio-oncologist needs to adjust the position of needles and seeds repeatedly to meet those requirements.

Therapeutic process

The patient was placed under local anesthesia, and the needles were punctured under the guidance of 3DPT. Before the seed implantation, 3DPT was positioned and attached on the skin with the assistance of a robot. The feasible workflow of the robot in positioning the template was described as follows. In the process of template positioning, there were two positions of the template to be determined: the initial position (IP) and target position (TP), as shown in Figure 3. Firstly, the patient and the robot (3DPT was clamped on the robot) are located on the CT table. A CT scanning (1st CT scanning) is performed for the patient and the template together. Secondly, CT images are transferred to BT-BTPS. The position of the template can be clearly identified in CT images and this is IP of the template. Before that, TP was determined in the preoperative planning. After the preoperative planning, we can get a template in BT-BTPS, and this position is TP. Finally, the relative position of IP and TP can be determined easily. In the template positioning, we sent the relative position of IP and TP to the robot, and the template can be moved from IP to TP.
In the template positioning process above, a new technology was involved. It is easy to find that IP is in the actual space, and TP is in the image space. The problem that needs to be solved is how to unify the positions of these two spaces into the same space. In this research, the relative position of the robot and the patient was kept unchanged, and a CT scanning was performed for the patient and the template (fixed on the end effector of the robot) together. Thus, IP and TP were all in the image space. It is easy to get the relative position of IP and TP in BT-BTPS, and control the robot to move the template from IP to TP.
During the surgery, the doctor inserted needles through the guiding holes on the template. Next, 125I seeds were implanted in the tumor target through the needles. The seed positions in the needle were calculated in the BT-BTPS, and the seeds interval in the same needle was at least 1.0 cm. Standardized treatment was carried out after the seed implantation surgery to prevent bleeding and infection.

Therapeutic evaluation

Post-operative validation
After implanting all seeds, a CT scanning was performed to verify whether the seeds were in the expected position. The CT images after implantation were imported to BT-BTPS. The radio-oncologist outlined the tumor target and identified all the seeds in CT images, so that the seeds could be clearly observed in three dimensions. Through displaying the isodose line, it could be observed, whether the PTV has been covered by the prescription dose. The actual dose distribution in the tumor target was evaluated using DVH. The DVH was compared with the implantation plan.
DVH evaluation
In this research, conformity index (CI) [26,27] and homogeneity index (HI) [28] were analyzed to establish their association with OS and LC. CI and HI were calculated using the DVH in the post-operative validation and the formulas were shown in Eq. (1) and Eq. (2).
Where VT was the total volume of the GTV; Vref was the total volume covered by the prescription dose isodose surface; VT,ref was the total volume of the GTV covered by the prescription dose isodose surface; D2 was the dose received by 2 percent of the GTV, regarded as the maximal dose; D98 was the dose received by 98 percent of the GTV, regarded as the minimal dose; Dref was the prescription dose in this plan.

Follow-up and statistical analysis

Follow-up was carried out every two months for the first year and every 6 months thereafter, including CT scanning, physical examination, and radiography. The changes in tumor size can be evaluated using the CT images. In this paper, the response evaluation criteria in solid tumors (RECIST) was used to evaluate the target lesions [29]. In this response, criteria were defined as: complete response (CR: disappearance of all target lesions); partial response (PR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter); stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started); progressive disease (PD: at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions). The recurrence mostly occurs within 2 years after the surgery and the diagnosis was confirmed by histopathology whenever required. Overall survival (OS) was calculated as the interval between the date of 125I seed brachytherapy and that of death, and if the patient was still alive, OS was censored by the last follow-up data. Local control (LC) was calculated from the date of 125I seed brachytherapy to the recurrence. OS and LC were estimated by the Kaplan-Meier method using the statistical product and service solutions (SPSS) 25.0 for Windows. The Cox regression was used to analyze the association of OS and LC with other factors. Significant association was confirmed when p < 0.05.

Ethical approval of the study protocol

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients provided written informed consent to participate in this study.


Outcome of seed implantation

In every surgery, the implantation plan, positioning of 3DPT, seed implantation, and post-operative validation were completely achieved. The median PTV was 35.21 cm3 (range, 14.36-102.35). Six to eighteen needles (median, 10) and 27-72 seeds (median, 35) were involved in every surgery to achieve the prescription dose of 110-140 Gy (median, 120 Gy). The time spent on each surgery ranged from 35-51 minutes (median, 42 minutes), while it spent 65-96 minutes (median, 78 minutes) using CCT. The steps of a surgery included CT scanning, positioning of a template, implantation of needles and seeds, and post-operative validation, excluding the preoperative planning and printing 3DPT. Therefore, the surgery time recorded in this research included the time spent on CT scanning, positioning of a template, implantation of needles and seeds, and post-operative validation. In the post-operative validation, the median dosimetry information were as follows: V100 was 95.3% (range, 92.4-109.8) and D90 was 126.1 Gy (range, 114.2-132.0). All the treatment parameters were summarized in Table 2, including information about CCTB.

Treatment effectiveness

The median follow-up time was 23 months (range, 8-42) and 25 months (range, 8-48) in RTDPTB and CCTB, respectively. The overall treatment effectiveness for all patients was collected and evaluated. In RTDPTB, the median OS was 30 months (95% confidence interval: 11.8-40.2), the median LC was 33 months (95% confidence interval: 28.6-37.4), and the 2-year OS and LC rates were 58.1% and 86.0%, respectively. In CCTB, the median follow-up time was 25 months (range, 8-48). The median OS was 20 months (95% confidence interval: 15.5-24.4), the median LC was 33 months (95% confidence interval: 19.1-46.9), and the 2-year OS and LC rates were 39.2% and 62.7%, respectively. Considering that the mixed tumor population can influence the accuracy and scientificity of the statistics, the treatment effectiveness for each kind of tumor type was summarized separately, including 2-year OS and LC rates, median OS and LC (Table 3).
The therapeutic efficacy of RTDPTB through the follow-up process is summarized in Table 1, and some typical cases are shown in Figure 4. Among the 43 patients, 20 (47%) patients achieved CR, 17 (39%) PR, 3 (7%) SD, and 3 (7%) PD, while there were 19 (38%) CR, 16 (32%) PR, 9 (17%) SD, and 7 (13%) PD in the 51 patients of CCTB.
Analysis of factors associated with overall survival and local control
In RTDPTB, median CI and HI were 0.93 (range, 0.89-0.96) and 2.97 (range, 2.18-6.51), respectively. While in the other reference method, they were 0.78 (range, 0.69-0.92) and 5.46 (range, 3.25-10.36), respectively.
Besides, we analyzed the following covariates associated with OS and LC: age, gender, and tumor size. The results of the association analysis are summarized in Table 4. The results demonstrated that CI (≤ or > 0.9) and HI (≤ or > 4) were significant factors in OS and LC (p < 0.05). And there were no association of OS and LC with other factors (age, gender, and tumor size).


For all patients, surgeries were performed successfully without massive bleeding during or after the surgery. Other complications related to the procedure that occurred during or after the surgery were analyzed. In CCTB, three patients were detected with small local hematomas (one in lung, one in pelvic cavity, and one in kidney) after inserting the needle, probably because of the injured small blood vessels. Two patients presented pneumothorax caused by coplanar puncture damage to lung tissue and recovered after drainage.
In RTDPTB, one patient had a small local hematoma in lung, and the symptom disappeared after symptomatic treatment. There were no severe radiation-related complications such as radioactive inflammation. The radiation-related complications as per the Radiation Therapy Oncology Group (RTOG) grading are summarized in Table 5. In CCTB, there were five patients presented fever symptoms, four of grade 1 and one of grade 2, and three patients were detected with leucopenia of grade 1. However, in RTDPTB, there were two patients presented fever symptoms of grade 1, and two patients were detected with grade 1 leucopenia. All those symptoms disappeared in two days after symptomatic treatment.


As of now, few articles report on the effectiveness and safety of robot-assisted 3DPT-guided 125I seed implantation. The aim of this work was the attempt to fill this gap. In order to obtain an accurate assessment, we selected as many cases as possible over a long period of time as well as a long follow-up. Finally, in RTDPTB, 43 patients with thoracoabdominal tumors were selected. Meanwhile, in CCTB, 51 patients with similar tumors were selected as reference. The patient characteristics in RTDPTB and CCTB were analyzed using SPSS. The results demonstrated that there were no significant differences in characteristics between the two groups, including gender, age, tumor size, diagnosis, and ECOG evaluation (p > 0.05, Table 1). Therefore, the comparison between RTDPTB and CCTB was significative.
For treatment of malignant tumors, a good effectiveness is mainly reflected in achieving an effective local control of the tumor and prolonging the survival time after a rationalized treatment. In order to evaluate this, OS and LC of RTDPTB were compared with that of CCTB. For different tumor type, the patients’ OS and LC maybe different. In order to improve the comparability, different tumor types were classified and compared between RTDPTB and CCTB (Table 3). However, the results demonstrated that the 2-year OS and LC rates of RTDPTB increased (18.9% and 23.3%, respectively) compared with that of CCTB, respectively, in the mixed tumor population. Statistical analysis showed that there was significant difference in 2-year OS (p = 0.015 < 0.05) and LC (p = 0.007 < 0.05), respectively. For classified population according to the tumor type, taking the lung cancer for example, the 2-year OS and LC rates (62.5% and 75%, respectively) of RTDPTB increased 20.8% and 16.7% compared with that (41.7% and 58.3%, respectively) of CCTB, respectively. Statistical analysis showed that there was significant difference in 2-year OS (p = 0.030 < 0.05) and LC (p = 0.025 < 0.05), respectively. The trend is also observed in other tumor types. Furthermore, the OS and LC rates of CCTB declined more quickly in the first two years after surgery (Figure 5), indicating that RTDPTB was more effective in the treatment of thoracoabdominal tumors.
Through the comprehensive association analysis, CI (p-value: 0.009 and 0.006 for OS and LC, respectively), HI (p-value: 0.008 and 0.006), and guidance approach (p-value: 0.009 and 0.010) were significant factors in OS and LC (p < 0.05, Table 4). Moreover, CI and HI in RTDPTB improved (19.2% and 45.6%, respectively) than that of CCTB (CI, 0.93 and 0.78 for RTDPTB and CCTB, respectively; HI, 2.97 and 5.46, respectively) (Table 2). Statistical analysis showed that between RTDPTB and CCTB there was significant difference in CI (p = 0.000 < 0.05) and HI (p = 0.000 < 0.05). No surprisingly, in CCTB, some regions of the tumor target cannot receive adequate radiation dose, leading to a poor local control and effectiveness. This was further conformed through DVH analysis. Under the guidance of 3DPT, the DVH of post-operative validation was almost identical to the implantation plan (Figure 6A). However, there was a large deviation between the two DVHs whenever using CCT (Figure 6B). To make a more comprehensive discussion, CI and HI of pre- and post-operation were also calculated and compared. In RTDPTB, the pre- and post-operation CI were both 0.95, and the pre- and post-operation HI were 1.91 and 2.02, respectively. In CCTB, the pre- and post-operation CI were 0.95 and 0.91, and the pre- and post-operation HI were 4.58 and 6.45, respectively. Obviously, CI and HI were almost the same in pre- and post-operation in RTDPTB, while there were significant differences in CCTB. The result indicated that the implantation plan could be much more effectively realized by using robot-assisted 3DPT. Based on this outcome, the tumor was effectively controlled, and survival time was lengthened.
To get a more comprehensive and reliable evaluation of effectiveness between RTDPTB and CCTB, several studies based on CCTB reported in the literature were also analyzed [29,30,31,32,33,34,35,36]. The relevant information was summarized in Table 6. Median survival time ranged from 7 to 22 months, and the 2-year OS rates were 10.7-52%. In our research with favorable outcomes, the median OS was 30 months and 2-year OS rate was 58.1%. Through comparative analysis, for every kind of tumor type, the 2-year OS rate of RTDPTB was higher than that reported in the relevant literature. These findings indicated that 125I seed implantation under the guidance of robot-assisted 3DPT was more effective than that of CCT.
The success of 125I seed brachytherapy depends on the accurate placement of radioactive seeds within the tumor target. When using CCTB for the treatment of cancer, there are several unsafe aspects. On one side, irra­diation damage to normal tissues around the tumor target may be induced due to the lower CI, which was discussed above. On the other side, all the parallel needle directions were perpendicular to the template.
That means, once the CCT was fixed, the needle direction was determined as well. The needle direction cannot be changed to avoid some vital organs. Only when the bones were thinner, they could be drilled to ensure the needles to pass. Otherwise, the implantation plans have to be given up, where there were vital organs or bones blocking the way. Therefore, the application of CCT would lead to a certain risk and limitations. Instead, the application of 3DPT had solved this problem and enhanced the safety. The needle could reach the expected position along a safe path through rotating a certain angle. In addition, 3DPT was produced exactly according to the patient’s skin, so it can be completely matched with the skin and reduce the difficulty in positioning. Hence, using 3DPT can meet the requirements for various tumor locations under safe conditions.
To better evaluate the safety of these two methods, the complications were collected and analyzed (Table 5). The incidence of radiation-related complications in RTDPTB (4.6% fever, 4.6% leucopenia, and 0% radioactive inflammation) was lower than in CCTB (9.8% fever, 5.9% leucopenia, and 0% radioactive inflammation). And there were no late complications observed during follow-up period. The risk of damaging vital blood vessels and organs can be greatly minimized in RTDPTB. Integrating the previous analysis, in can be demonstrated that RTDPTB can achieve a good safety.
In addition, 125I seed implantation surgery with CCT takes usually 78 minutes, while it takes only 42 minutes using robot-assisted 3DPT. It was also an indicator in the evaluation of safety. For 125I seed brachytherapy, long time spent on surgery indicated great damage to the patient. There may be two reasons: 1. CCT positioning is difficult and repeated CT scanning was time consuming and harmful to the patient; 2. Drilling holes on the thin rib would consume a lot of time, and it also causes damage to patient. Consequently, the less time-consuming process in RTDPTB reached a better safety.
In the end, the dose planning and dose optimization of these cases in this research were achieved manually, not by automatic inverse planning. Therefore, it will have a certain impact on the results between RTDPTB and CCTB caused by manual planning and optimizing. In this research, we have tried to reduce this impact. In the final dose optimization, in addition to meeting the basic conditions (V100 > 90%, V150 < 50%, V200 < 20%), we tried to choose the solution that makes the DVH optimal. At present, the automatic inverse optimization has been achieved. In the future work, we will eliminate the interference of manual planning to more accurately evaluate the effectiveness and safety of RTDPTB.


Through our research and comparisons with other studies, robot-assisted 3DPT shows sufficient effectiveness and safety in 125I seed brachytherapy for the treatment of thoracoabdominal tumors. It is proved to be more effective, better tolerated, and less time-consuming. This research was based on a small number of patients and relatively short follow-up time. Hence, a larger patient cohort and longer follow-up periods should be involved to reach a more definite conclusion in the future research.


We gratefully acknowledge our research team at the Center for Advanced Mechanisms and Robotics, Tianjin University, for their technical assistance. The Department of Oncology of the Second Hospital of Tianjin Medical University provided great support regarding the clinical experimental environment and equipment.
This work was supported by the National Natural Science Foundation of China (Grant No. 51775368), the National Natural Science Foundation of China (Grant No. 5171101938), and the Technology Planning Project of Guangdong Province, China (Grant No. 2017B020210004).


The authors report no conflict of interest.


1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Chen W, Zheng R, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115-132.
3. Thorn CF, Oshiro C, Marsh S et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011; 21: 440-446.
4. Florea AM, Büsselberg D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers (Basel) 2011; 3: 1351-1371.
5. Kawalec P, Łopuch S, Mikrut A. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis. Clin Breast Cancer 2015; 15: 90-100.
6. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237: 74-85.
7. Van Mierlo KM, Schaap FG, Dejong CH et al. Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure. J Hepatol 2016; 65: 1217-1231.
8. Jagsi R, Momoh AO, Qi J et al. Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction. J Natl Cancer Inst 2018; https://doi.org/10.1093/jnci/djx148.
9. Yao L, Jiang Y, Jiang P et al. CT-guided permanent 125I seed interstitial brachytherapy for recurrent retroperitoneal lymph node metastases after external beam radiotherapy. Brachytherapy 2015; 14: 662-669.
10. Li J, Zhang L, Xu W et al. Computed tomography-guided implantation of 125I seeds brachytherapy for recurrent multiple pulmonary oligometastases: initial experience and results. J Contemp Brachytherapy 2017; 9: 132-138.
11. Lu M, Yao W, Zhang T et al. Feasibility and Efficacy of Microwave Ablation Combined with Iodine-125 Seed Implantation in Local Control of Recurrent Retroperitoneal Liposarcomas: Initial Clinical Experience. Oncologist 2017; 22: 1500-1505.
12. Sylvester J, Grimm P, Naidoo D et al. First report on the use of a thinner 125 I radioactive seed within 20-gauge needles for permanent radioactive seed prostate brachytherapy: Evaluation of postimplant dosimetry and acute toxicity. Brachytherapy 2013; 12: 375-381.
13. Huo X, Huo B, Wang H et al. Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage III non-small cell lung cancer. J Contemp Brachytherapy 2017, 9: 527-534.
14. Li J, Xie Q, Wang W et al. CT-guided implantation of I-125 seeds (permanent brachytherapy) for metastatic tumors of the hepatic portal system: Effectiveness and safety in 13 patients. Brachytherapy 2016; 15: 224-230.
15. Huo X, Huo B, Wang H et al. Percutaneous computed tomography-guided permanent 125I implantation as therapy for pulmonary metastasis. J Contemp Brachytherapy 2018; 10: 132-141.
16. Martinez-Monge R, Nag S, Nieroda CA et al. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer 2015; 85: 1218-1225.
17. Chai SD, Zheng GJ, Mao YQ et al. CT guided transcutaneous interstitial implantation of (125)I seeds for lung carcinoma. Chinese J Radiat Oncol 2004; 13: 291-293.
18. Huang MW, Liu SM, Zheng L et al. A digital model individual template and CT-guided 125I seed implants for malignant tumors of the head and neck. J Radiat Res 2012; 53: 973-977.
19. Ji Z, Jiang Y, Su L et al. Dosimetry Verification of (125)I Seeds Implantation With Three-Dimensional Printing Noncoplanar Templates and CT Guidance for Paravertebral/Retroperitoneal Malignant Tumors. Technol Cancer Res Treat 2017; 16: 1044-1050.
20. Wang H, Wang JJ, Jiang YL et al. CT guidance 125I seed implantation for pelvic recurrent rectal cancer assisted by 3D printing individual non-coplanar template. Zhonghua Yi Xue Za Zhi 2016; 96: 3782-3786 [Article in Chinese].
21. Lin L, Wang J, Jiang Y et al. Interstitial 125I Seed implantation for cervical lymph node recurrence after multimodal treatment of thoracic esophageal squamous cell carcinoma. Technol Cancer Res Treat 2015; 14: 201-207.
22. Han T, Yang X, Xu Y et al. Therapeutic value of 3-D printing template-assisted I-125-seed implantation in the treatment of malignant liver tumors. Oncotargets Ther 2017; 10: 3277-3283.
23. Dou H, Jiang S, Yang Z et al. Design and validation of a CT-guided robotic system for lung cancer brachytherapy. Med Phys 2017; 44: 4828-4837.
24. Nath R, Anderson LL, Luxton G et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPMRadiation Therapy Committee Task Group No. 43. Med Phys 1999; 26: 2514-2520.
25. Rivard MJ, Coursey BM, DeWerd LA et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004; 31: 633-674.
26. Yang B, Sun X, Pang H et al. Dosimetric analysis of rib interference of the CTV during interstitial brachytherapy of lung tumors. J Contemp Brachytherapy 2017; 9: 566-571.
27. Feuvret L, Noël G, Mazeron JJ et al. Conformity index: A review. Int J Radiat Oncol Biol Phys 2006; 64: 333-342.
28. Kataria T, Sharma K, Subramani V et al. Homogeneity Index: An objective tool for assessment of conformal radiation treatments. J Med Phys 2012; 37: 207-213.
29. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
30. Wang Z, Liu Y, Liu F et al. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer. Eur Radiol 2010; 20: 1786-1791.
31. Liu K, Ji B, Zhang W et al. Comparison of Iodine-125 Seed Implantation and Pancreaticoduodenectomy in the Treatment of Pancreatic Cancer. Int J Med Sci 2014; 11: 893-896.
32. Shi L, Wu C, Wu J et al. Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer. Radiat Oncol 2012; 7: 114-123.
33. Huo XD, Wang HX, Yang JK et al. Effectiveness and safety of CT-guided 125I seed brachytherapy for postoperative locoregional recurrence in patients with nonesmall cell lung cancer. Brachytherapy 2016; 15: 370-380.
34. Zhang L, Chen L, Wang J et al. CT-guided radioactive I-125 seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma. Clin Radiol 2014; 69: 624-629.
35. Wang JJ, Yuan HS, Li JN et al. CT-guided radioactive seed implantation for recurrent rectal carcinoma after multiple therapy. Med Oncol 2010; 27: 421-429.
36. Karam SD, Horne ZD, Hong RL et al. Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer. Radiat Oncol 2013; 8: 179.
37. Lu M, Pu D, Zhang W et al. Trans-bronchoscopy with implantation of I-125 radioactive seeds in patients with pulmonary atelectasis induced by lung cancer. Oncol Lett 2015; 10: 216-222.
Copyright: © 2018 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe